The weeks right after someone stops using opioids are the most dangerous stretch of the entire process. Medication changes those odds, and understanding how it works can make the next decision clearer.
Clinically reviewed by the Serenity at Summit clinical team · July 2026
If you or someone you love has just made it through the worst of opioid withdrawal, the relief is real. So is a danger most people are never warned about. The first weeks after opioids leave the body are, statistically, the most likely time for a fatal overdose. That holds true whether you are reading this at a kitchen table in Union County or in a waiting room off I-495 in Haverhill, and it is the exact window that medication-assisted treatment was designed to protect.
Medication-assisted treatment, usually shortened to MAT, combines an FDA-approved medication with counseling and medical care. For opioid use disorder, that medication is almost always buprenorphine, methadone, or naltrexone. Started at the right time, often during a medically supervised opioid detox and continued through a structured medication-assisted treatment program, these medications do something willpower alone cannot: they keep people alive long enough for the rest of recovery to take hold.
What Medication-Assisted Treatment Actually Is
Many families hear the word “medication” and worry that their loved one is simply trading one substance for another. That worry is understandable, and it deserves a real answer instead of a slogan. Medication-assisted treatment is a clinical approach that uses a specific, prescribed medicine to steady the brain and body while a person rebuilds a life. For opioid use disorder specifically, clinicians increasingly call this medications for opioid use disorder, or MOUD.
Three medications carry the strongest evidence. Each one works on the same target in the brain, the opioid receptor, but each does so in a very different way.
- Buprenorphine: a partial opioid medication that quiets withdrawal and cravings by switching the brain’s opioid receptors on only partway, with a built-in limit on how far it can go. It is often prescribed as Suboxone, which combines buprenorphine with naloxone to discourage misuse.
- Methadone: a long-acting opioid medication, taken once a day under supervision, that holds the receptors at a steady, even level so there is no high and no crash between doses.
- Naltrexone: a blocker that is not an opioid at all. It sits on the receptors so opioids cannot attach and cannot produce a high. The long-acting monthly injection is known as Vivitrol, and it is started only after the body is fully clear of opioids.
Alongside the medication, treatment includes counseling and medical monitoring and a plan for what comes next. The medicine is the piece that keeps a person safe enough to do that harder, slower work.
Why the First Weeks of Recovery Are the Most Dangerous
Opioid tolerance falls fast. Within days of the last dose, the body loses much of its ability to handle the amounts it once took every day. This is the cruel part that catches so many families off guard: the dose that felt routine a month ago can stop a person’s breathing now. Most overdose deaths in early recovery are not the result of someone giving up. They happen because tolerance dropped, a person used again in a moment of stress or pain, and the amount their body could once survive was suddenly far too much.
The risk is highest in the first days and weeks after detox, after a hospital stay, or after release from jail, exactly when people are told they are “clean” and often have the least protection. A large 2017 review in The BMJ that pooled data from many countries measured the size of that gap. People who were out of methadone treatment had roughly three times the all-cause death rate and close to five times the overdose death rate of people who stayed on the medication.
This is why stopping at detox is rarely enough on its own. Clearing the drug from the body treats the first five to seven days. It does not touch the months of high overdose risk that follow. Medication carries protection across that whole window, which is why good care continues well past the last day of opioid withdrawal.
What the Research Shows About Medication and Survival
One of the most persuasive studies on this question was done close to home, in Massachusetts. Researchers followed more than 17,000 adults who had survived an opioid overdose and looked at what happened over the next 12 months. The findings, published in Annals of Internal Medicine in 2018, were stark. Within that Massachusetts group, people who received methadone had roughly half the risk of dying from any cause (adjusted hazard ratio 0.47), and people who received buprenorphine had about a third lower risk (0.63), compared with those who got no medication at all.
Those numbers describe that specific group of patients rather than a guarantee for any one person, but they point the same direction as decades of other research. Staying on buprenorphine or methadone is tied again and again to lower overdose death and lower death from any cause. Clinical reviews of opioid use disorder treatment reach the same conclusion: detox by itself, without ongoing medication, carries a high rate of return to use and a high rate of overdose, while medication sustained over time is associated with survival. National modeling published in JAMA Psychiatry has also found medication-based treatment to be both clinically effective and cost-effective compared with no treatment, which matters for anyone weighing whether care is worth it.
One more medication belongs in every early-recovery plan, and it works as emergency rescue rather than daily treatment. Naloxone is the nasal spray that can restart breathing during an overdose in progress. It is easy to confuse naloxone with naltrexone because the names sit so close together, but they do different jobs. Naltrexone is a daily or monthly blocker taken as treatment, while naloxone is the spray kept nearby for a crisis. Anyone leaving detox should carry it and teach the people around them how to use it, so it helps to know exactly how naloxone works before that moment ever arrives.
Why Medication-Assisted Treatment Is Not “Swapping One Addiction for Another”
This is the objection that stops many people from starting, and it deserves to be taken seriously rather than waved away. In recovery meetings, in families, and sometimes from otherwise well-meaning people, someone in treatment may hear that they are “still using.” The pharmacology tells a different story, and it starts with how these medications actually behave in the brain.
Buprenorphine is a partial agonist, which means it switches the opioid receptors on only partway and then reaches a ceiling where more medication produces no more effect. That ceiling is a safety feature, and it is a large part of why buprenorphine is far less likely to slow breathing to a fatal level. Because it is long-acting and steady, it does not create the surge and crash that drives compulsive use. Methadone, though a full opioid, is dosed once daily to sit at an even blood level, so a person on a stable dose is not riding waves up and down all day. Naltrexone contains no opioid at all and simply blocks the receptors. A person taking any of the three, at the right dose, is not intoxicated. They can drive, work a shift along the Garden State Parkway, pick up their kids, and hold a steady conversation.
There is also an important clinical distinction underneath the myth. Physical dependence is not the same thing as addiction. Dependence means the body has adapted to a medication and would feel withdrawal if it stopped abruptly, which is also true of many blood-pressure and antidepressant medicines that no one calls an addiction. Addiction is a pattern of compulsive use that continues despite mounting harm, alongside a loss of control. Steady, prescribed medication that removes cravings and lets someone rebuild a life sits close to the opposite of that pattern. Understanding the difference between addiction and dependence is where much of the confusion clears.
Starting Medication-Assisted Treatment in New Jersey and Massachusetts
Knowing that medication saves lives is one thing. Getting through the first hours safely, with the medication started correctly, is another, and it is where a medically supervised setting earns its place. Serenity at Summit is built around exactly this handoff, from the acute danger of withdrawal to the steadier ground of ongoing treatment.
Both Serenity at Summit locations provide medically monitored inpatient detox at ASAM Level 3.7, the level of care designed for higher-risk withdrawal, with around-the-clock nursing on the unit and comfort medications to ease the worst symptoms. Buprenorphine or methadone can be started during that stay so a person is already protected as they move into residential treatment, and naltrexone can be arranged once the body is fully clear. Because opioid use disorder so often travels with depression, anxiety, or trauma, treatment here addresses those co-occurring mental health conditions rather than the substance use alone.
The two campuses put medically supported detox within reach of most of the region. The Union, New Jersey location sits in Union County, close to Newark, Elizabeth, and the wider New York City metro by way of the Garden State Parkway and the New Jersey Turnpike. The Haverhill, Massachusetts location serves Essex County and the Merrimack Valley, drawing from Lawrence, Lowell, Methuen, the southern New Hampshire border, and the greater Boston area along I-495 and I-93. Wherever a person is starting from, the drive out of the environment tied to their use is often the first protective step.
When You Are Ready to Take This Step, We Are Here
If you have read this far, you are probably weighing a hard decision, either for yourself or for someone whose safety has been keeping you up at night. You do not have to have it all figured out before you reach out. The admissions team at Serenity at Summit can talk you through how medication-assisted treatment would work in your situation, what detox and residential care actually involve, and can help you understand what your plan covers, in plain language and without pressure. You can begin that conversation through the Serenity at Summit admissions page. When that time comes, our team is here for it.
Frequently Asked Questions About How MAT Saves Lives in Early Recovery
No. Buprenorphine, methadone, and naltrexone work in ways that are pharmacologically different from active drug use. At the right dose they steady the brain rather than producing a high, so a person can drive, work, and take care of their family. Physical dependence on a prescribed, steady medication is not the same as the loss of control and compulsive use that define addiction.
There is no fixed endpoint. Some people take medication for months, others for years, and some stay on it indefinitely, because longer time in treatment is linked to better survival and lower relapse. If and when to taper is a clinical decision made with the prescriber over time, never a race to stop as quickly as possible.
The right choice depends on the person, their history, and their preferences. Buprenorphine and methadone carry the strongest evidence for reducing overdose and death, while naltrexone is a non-opioid blocker that requires the body to be fully clear of opioids before it can be started. A medical team helps match the medication to the individual.
Yes. Buprenorphine or methadone is often started during a medically supervised detox so a person is protected before the highest-risk window even opens. Naltrexone is added later, after opioids have fully cleared the body. Beginning medication in a monitored setting is one of the safest ways to enter recovery.
